Clinical trial
Myfortic - Treatment for Extensive cGvHD
NCT00298324 · European Society for Blood and Marrow Transplantation, Other · Terminated
Key facts
| NCT number | NCT00298324 |
|---|---|
| Title | Myfortic - Treatment for Extensive cGvHD |
| Official title | A Randomized Double Blinded Placebo-Controlled Phase III Trial Comparing Cyclosporine Plus Steroids With or Without Myfortic as Primary Treatment for Extensive Chronic Graft Versus Host Disease |
| Lead sponsor | European Society for Blood and Marrow Transplantation, Other |
| Collaborators | Novartis Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Graft vs Host Disease |
| Intervention type | Drug |
| Interventions | Myfortic, Prednisone and Cyclosporine |
| Enrollment | 34 |
| Start date | Sep 1, 2006 |
| Primary completion | Nov 1, 2009 |
| Completion | Nov 1, 2010 |
| First posted | Mar 2, 2006 |
| Last update posted | Apr 3, 2015 |
| Countries | France, Germany, Italy, Netherlands, Spain, Sweden, Switzerland, Turkey (Türkiye) |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: